Last updated: March 21, 2026
What is the Drug NDC: 70710-2139?
The NDC 70710-2139 corresponds to Eptacog Alfa (Recombinant), marketed as Sevenfacta by Novo Nordisk. It is a recombinant coagulation factor used primarily for the treatment of bleeding episodes in Hemophilia A or B patients with inhibitors. Approved by the FDA in 2022, it is part of a class of bypassing agents designated for patients with inhibitors resistant to standard therapies.
Market Overview
Market Size and Growth Drivers
- The global hemophilia treatment market was valued at approximately USD 12 billion in 2022 (Grand View Research, 2022).
- The hemophilia A segment dominates, comprising over 70% of the market due to higher prevalence.
- The global hemophilia population is estimated at 420,000 with growing diagnosis rates facilitated by improved awareness and diagnostic capabilities.
Key Factors Influencing Market Dynamics
- Incidence of Hemophilia: Approximately 1 in 5,000 male births globally.
- Inhibitor Development: Occurs in about 30% of Hemophilia A patients, increasing reliance on bypassing agents like Sevenfacta.
- Advances in Gene Therapy: Potential to shift treatment paradigms and decrease demand for bypassing agents over the long term.
Market Participants
- Companies actively marketing bypassing agents include Pfizer (Beyfortus), Bioverativ (Obizur), and Novo Nordisk (Sevenfacta).
- Competition centers on efficacy, safety profile, administration route, and cost.
Pricing Analysis
Current Pricing Benchmarks
- Sevenfacta: List price per vial is approximately USD 3,000.
- Other common bypassing agents:
- FEIBA (Takeda): USD 4,000–USD 5,000 per infusion.
- NovoSeven (Sobi): USD 3,500 per vial.
Cost Factors
- Dosing depends on body weight and severity of bleeding.
- Estimated average dose: 50-100 units/kg.
- Average treatment course (per bleeding episode): USD 10,000–USD 20,000.
Reimbursement Landscape
- Reimbursement varies across payers and regions.
- Insurance coverage and patient assistance programs mitigate out-of-pocket costs.
Price Projections
| Year |
Estimated Price per Vial |
Key Assumptions |
| 2023 |
USD 3,000 |
Current list price, limited market penetration in early stages |
| 2025 |
USD 2,800–USD 3,200 |
Competitive pressure, potential price adjustments from payers |
| 2030 |
USD 2,500–USD 3,000 |
Market stabilization, increased acceptance, and potential volume growth |
The pricing trend reflects a gradual decrease driven by market competition, biosimilar entry, and payer negotiations. Long-term, prices may stabilize around USD 2,500–USD 3,000 per vial.
Market Penetration and Growth Projections
- Initial adoption (2022–2023): Focused on centers with high inhibitor prevalence.
- Medium-term (2024–2026): Expansion into broader Hemophilia A populations with inhibitors.
- Long-term (2027–2030): Growing preference due to efficacy and safety profile, with projected annual sales reaching USD 500–USD 800 million globally.
Regional Variations
- North America: Dominates, with 60% of sales—driven by high diagnosis rates and insurance coverage.
- Europe and Asia-Pacific: Rapid growth expected, influenced by increasing diagnosis and access.
Risks and Challenges
- Biosimilar competition may pressure prices.
- Long-term safety data influences payer decisions.
- The emergence of gene therapy could reduce long-term demand for bypassing agents.
Key Takeaways
- The market for recombinant bypassing agents, including Sevenfacta, remains lucrative but faces downward pressure due to biosimulation and gene therapy developments.
- Current pricing per vial hovers around USD 3,000, with projections suggesting a slight decrease over the next decade.
- Market growth will be driven by increased diagnosis, inhibitor prevalence, and treatment adoption in emerging markets.
- Competitive landscape, payer negotiations, and innovation will shape long-term pricing strategies.
FAQs
Q1: How does the price of Sevenfacta compare to other bypassing agents?
Sevenfacta’s list price per vial (~USD 3,000) is comparable to NovoSeven but lower than FEIBA. Variations depend on region and payer negotiations.
Q2: What factors could influence the price of Elevenfacta in the future?
Market competition, biosimilar entries, payer pressure, and approval of new therapies like gene editing.
Q3: What is the expected market size for Sevenfacta over the next five years?
Annual sales could reach USD 500–USD 800 million globally, contingent on market penetration and treatment adoption rates.
Q4: How does inhibitor prevalence affect market potential?
With approximately 30% of Hemophilia A patients developing inhibitors, therapies like Sevenfacta are critical, expanding the market as inhibitor management remains necessary.
Q5: What regional factors influence pricing?
Healthcare policies, reimbursement frameworks, and prevalence influence regional pricing. North America maintains higher prices due to reimbursement structures.
References
- Grand View Research. (2022). Hemophilia Market Size, Share & Trends Analysis Report.
- National Hemophilia Foundation. (2021). Hemophilia Facts and Statistics.
- U.S. Food and Drug Administration. (2022). FDA Approvals for Hemophilia Treatments.
